⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 18, 2024BJC ReportsOpen Access

Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors

Michael Conroy Hazel O’Sullivan Delwood C. Collins Richard Bambury Derek G. Power Stuart A. Grossman Séamus O’Reilly

View Full Paper

Ask AI

Bookmark

Share

Abstract

The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Conroy et al. (2024) studied this question.

synapsesocial.com/papers/68e6e8a8b6db6435876637e5 https://doi.org/10.1038/s44276-024-00058-6

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer AnalysisCohort Study · 2026
2Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium2024 · 11 citations
3Baseline and On-Treatment Absolute Lymphocyte Count-Defined Lymphopenia in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review With Structured Qualitative SynthesisSystematic Review · 2026
4Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditiscase-control · 2020 · 75 citations
5Lymphocyte activation markers predict the therapeutic response to immune checkpoint inhibitors: A case–control study2024 · 1 citations